Logo

Exact Sciences: Paul Clancy

Mar 19, 2021

Exact Sciences has appointed Paul Clancy as a Class I member of its board. In connection with his appointment, Clancy was also named to the board's audit and finance committee.

Clancy has more than 30 years of experience in financial management and strategic business planning, and served as the executive vice president and CFO of Alexion Pharmaceuticals from July 2017 to November 2019. Prior to joining Alexion, he served in several positions at Biogen, including executive VP of finance and CFO. Before Biogen, Clancy spent 13 years serving in a variety of financial and general management positions at PepsiCo. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.